Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders

Trends in Molecular Medicine

Volumn 17, Issue 2, 2011, Pages 78-87

  Ehninger, Dan ^a   Silva, Alcino J ^b  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

AUTISM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; HETEROZYGOTE; NEUROLOGIC DISEASE; NONHUMAN; REVIEW; TUBEROUS SCLEROSIS;

ANIMALS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; MUTATION; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA;

EID: 79651475390     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.10.002     Document Type: Review

References (129)

1. European Chromosome 16 Tuberous Sclerosis Consortium (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75, 1305-1315.
2. van Slegtenhorst M., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277:805-808.
3. Osborne J.P., et al. Epidemiology of tuberous sclerosis. Ann. N. Y. Acad. Sci. 1991, 615:125-127.
4. Crino P.B., et al. The tuberous sclerosis complex. N. Engl. J. Med. 2006, 355:1345-1356.
5. Osborne J.P., et al. Non-penetrance in tuberous sclerosis. Lancet 2000, 355:1698.
6. Ehninger D., et al. From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J. Intellect. Disabil. Res. 2009, 53:838-851.
7. Silva A.J., Ehninger D. Adult reversal of cognitive phenotypes in neurodevelopmental disorders. J. Neurodev. Disord. 2009, 1:150-157.
8. Ehninger D., et al. Reversing neurodevelopmental disorders in adults. Neuron 2008, 60:950-960.
9. Critchley M., Earl C. Tuberous sclerosis and allied conditions. Brain 1932, 55:311-346.
10. Kanner L. Autistic disturbances of affective contact. Nerv. Child 1943, 2:217-250.
11. Smalley S.L. Autism and tuberous sclerosis. J. Autism Dev. Disord. 1998, 28:407-414.
12. Bolton P.F., et al. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain 2002, 125:1247-1255.
13. de Vries P.J., et al. The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families. Eur. Child Adolesc. Psychiatry 2007, 16:16-24.
14. Prather P., de Vries P.J. Behavioral and cognitive aspects of tuberous sclerosis complex. J. Child Neurol. 2004, 19:666-674.
15. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J. Autism Dev. Disord. 2003, 33:365-382.
16. Hunt A., Dennis J. Psychiatric disorder among children with tuberous sclerosis. Dev. Med. Child Neurol. 1987, 29:190-198.
17. Gillberg I.C., et al. Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study. Dev. Med. Child Neurol. 1994, 36:50-56.
18. Hunt A., Shepherd C. A prevalence study of autism in tuberous sclerosis. J. Autism Dev. Disord. 1993, 23:323-339.
19. Butler M.G., et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J. Med. Genet. 2005, 42:318-321.
20. Rosner M., et al. The mTOR pathway and its role in human genetic diseases. Mutat. Res. 2008, 659:284-292.
21. Campbell D.B., et al. A genetic variant that disrupts MET transcription is associated with autism. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:16834-16839.
22. Levitt P., Campbell D.B. The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. J. Clin. Invest. 2009, 119:747-754.
23. Zafeiriou D.I., et al. Childhood autism and associated comorbidities. Brain Dev. 2007, 29:257-272.
24. Williams P.G., Hersh J.H. Brief report: the association of neurofibromatosis type 1 and autism. J. Autism Dev. Disord. 1998, 28:567-571.
25. Johannessen C.M., et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8573-8578.
26. Neves-Pereira M., et al. Deregulation of EIF4E: a novel mechanism for autism. J. Med. Genet. 2009, 46:759-765.
27. Vanderklish P.W., Edelman G.M. Differential translation and fragile X syndrome. Genes Brain Behav. 2005, 4:360-384.
28. Hagerman R.J., Hagerman P.J. The fragile X premutation: into the phenotypic fold. Curr. Opin. Genet. Dev. 2002, 12:278-283.
29. Bassell G.J., Warren S.T. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008, 60:201-214.
30. Bear M.F., et al. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27:370-377.
31. Dolen G., et al. Correction of fragile X syndrome in mice. Neuron 2007, 56:955-962.
32. Sharma A., et al. Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci. 2010, 30:694-702.
33. Hentges K.E., et al. FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:13796-13801.
34. Kumar V., et al. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J. Neurosci. 2005, 25:11288-11299.
35. Jaworski J., et al. Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J. Neurosci. 2005, 25:11300-11312.
36. Choi Y.J., et al. Tuberous sclerosis complex proteins control axon formation. Genes Dev. 2008, 22:2485-2495.
37. Chow D.K., et al. Laminar and compartmental regulation of dendritic growth in mature cortex. Nat. Neurosci. 2009, 12:116-118.
38. Zhou J., et al. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J. Neurosci. 2009, 29:1773-1783.
39. Geschwind D.H., Levitt P. Autism spectrum disorders: developmental disconnection syndromes. Curr. Opin. Neurobiol. 2007, 17:103-111.
40. Zeng L.H., et al. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J. Neurosci. 2009, 29:6964-6972.
41. Murthy V., et al. Developmental expression of the tuberous sclerosis proteins tuberin and hamartin. Acta Neuropathol. 2001, 101:202-210.
42. Tang S.J., et al. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:467-472.
43. Kelleher R.J., et al. Translational regulatory mechanisms in persistent forms of synaptic plasticity. Neuron 2004, 44:59-73.
44. Tavazoie S.F., et al. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat. Neurosci. 2005, 8:1727-1734.
45. Ehninger D., et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat. Med. 2008, 14:843-848.
46. Uhlmann E.J., et al. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann. Neurol. 2002, 52:285-296.
47. Wong M., et al. Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. Ann. Neurol. 2003, 54:251-256.
48. Zeng L.H., et al. Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiol. Dis. 2007, 28:184-196.
49. Curatolo P., et al. Tuberous sclerosis. Lancet 2008, 372:657-668.
50. Goorden S.M., et al. Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures. Ann. Neurol. 2007, 62:648-655.
51. Young D.M., et al. Altered ultrasonic vocalizations in a tuberous sclerosis mouse model of autism. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:11074-11079.
52. Hoeffer C.A., et al. Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior. Neuron 2008, 60:832-845.
53. Harrar Y., et al. FKBPs: at the crossroads of folding and transduction. Trends Plant Sci. 2001, 6:426-431.
54. Kwon C.H., et al. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12923-12928.
55. Brillantes A.B., et al. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell 1994, 77:513-523.
56. Meikle L., et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J. Neurosci. 2008, 28:5422-5432.
57. Meikle L., et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J. Neurosci. 2007, 27:5546-5558.
58. Fields R.D. White matter in learning, cognition and psychiatric disorders. Trends Neurosci. 2008, 31:361-370.
59. de Vries P.J., Howe C.J. The tuberous sclerosis complex proteins - a GRIPP on cognition and neurodevelopment. Trends Mol. Med. 2007, 13:319-326.
60. Erbayat-Altay E., et al. The natural history and treatment of epilepsy in a murine model of tuberous sclerosis. Epilepsia 2007, 48:1470-1476.
61. Zeng L.H., et al. Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex. Neurobiol. Dis. 2010, 37:764-771.
62. Zeng L.H., et al. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann. Neurol. 2008, 63:444-453.
63. Katagiri H., et al. Requirement of appropriate glutamate concentrations in the synaptic cleft for hippocampal LTP induction. Eur. J. Neurosci. 2001, 14:547-553.
64. Zoghbi H.Y. Postnatal neurodevelopmental disorders: meeting at the synapse?. Science 2003, 302:826-830.
65. Bourgeron T. A synaptic trek to autism. Curr. Opin. Neurobiol. 2009, 19:231-234.
66. Wang Y., et al. A role for the mTOR pathway in surface expression of AMPA receptors. Neurosci. Lett. 2006, 401:35-39.
67. von der Brelie C., et al. Impaired synaptic plasticity in a rat model of tuberous sclerosis. Eur. J. Neurosci. 2006, 23:686-692.
68. Happe F., Frith U. The weak coherence account: detail-focused cognitive style in autism spectrum disorders. J. Autism Dev. Disord. 2006, 36:5-25.
69. Raab-Graham K.F., et al. Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites. Science 2006, 314:144-148.
70. Scheetz A.J., et al. NMDA receptor-mediated control of protein synthesis at developing synapses. Nat. Neurosci. 2000, 3:211-216.
71. Jung C.H., et al. mTOR regulation of autophagy. FEBS Lett. 2010, 584:1287-1295.
72. White R.J., Sharrocks A.D. Coordinated control of the gene expression machinery. Trends Genet. 2010, 26:214-220.
73. Hoffman D.A., et al. K+ channel regulation of signal propagation in dendrites of hippocampal pyramidal neurons. Nature 1997, 387:869-875.
74. Frick A., et al. LTP is accompanied by an enhanced local excitability of pyramidal neuron dendrites. Nat. Neurosci. 2004, 7:126-135.
75. Meiri N., et al. Reversible antisense inhibition of Shaker-like Kv1.1 potassium channel expression impairs associative memory in mouse and rat. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:4430-4434.
76. Gratacos E., et al. Kv1.1 channel antisense attenuates learning and modulation of dentate polysialylated NCAM. Neuroreport 1998, 9:2727-2731.
77. Costa-Mattioli M., et al. eIF2alpha phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell 2007, 129:195-206.
78. Ozcan U., et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol. Cell 2008, 29:541-551.
79. Bolduc F.V., et al. Excess protein synthesis in Drosophila fragile X mutants impairs long-term memory. Nat. Neurosci. 2008, 11:1143-1145.
80. Chuang S.C., et al. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J. Neurosci. 2005, 25:8048-8055.
81. Hou L., Klann E. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J. Neurosci. 2004, 24:6352-6361.
82. McBride S.M., et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005, 45:753-764.
83. Yan Q.J., et al. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005, 49:1053-1066.
84. de Vrij F.M., et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol. Dis. 2008, 31:127-132.
85. Suvrathan A., et al. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:11591-11596.
86. Silva A.J., et al. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat. Genet. 1997, 15:281-284.
87. Li W., et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr. Biol. 2005, 15:1961-1967.
88. Costa R.M., et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 2002, 415:526-530.
89. Joinson C., et al. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol. Med. 2003, 33:335-344.
90. de Vries P.J., Prather P.A. The tuberous sclerosis complex. N. Engl. J. Med. 2007, 356:92. author reply 93-94.
91. Ridler K., et al. Neuroanatomical correlates of memory deficits in tuberous sclerosis complex. Cereb. Cortex 2007, 17:261-271.
92. Webb D.W., et al. Morbidity associated with tuberous sclerosis: a population study. Dev. Med. Child Neurol. 1996, 38:146-155.
93. Muzykewicz D.A., et al. Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex. Epilepsy Behav. 2007, 11:506-513.
94. Bolton P.F., Griffiths P.D. Association of tuberous sclerosis of temporal lobes with autism and atypical autism. Lancet 1997, 349:392-395.
95. Weber A.M., et al. Autism and the cerebellum: evidence from tuberous sclerosis. J. Autism Dev. Disord. 2000, 30:511-517.
96. Eluvathingal T.J., et al. Cerebellar lesions in tuberous sclerosis complex: neurobehavioral and neuroimaging correlates. J. Child Neurol. 2006, 21:846-851.
97. Asano E., et al. Autism in tuberous sclerosis complex is related to both cortical and subcortical dysfunction. Neurology 2001, 57:1269-1277.
98. Benvenuto G., et al. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000, 19:6306-6316.
99. Lamb R.F., et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat. Cell Biol. 2000, 2:281-287.
100. Kwiatkowski D.J., Manning B.D. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum. Mol. Genet. 2005, 14(Spec. No. 2):R251-258.
101. Costa-Mattioli M., et al. Translational control of long-lasting synaptic plasticity and memory. Neuron 2009, 61:10-26.
102. Gong R., et al. Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons. J. Biol. Chem. 2006, 281:18802-18815.
103. Fumagelli S., Thomas G. S6 phosphorylation and signal transduction. Translational Control of Gene Expression 2000, 695-717. Cold Spring Harbor Laboratory Press. N. Sonenberg (Ed.).
104. Manning B.D., et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 2002, 10:151-162.
105. Inoki K., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4:648-657.
106. Ma L., et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121:179-193.
107. Takei N., et al. Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites. J. Neurosci. 2004, 24:9760-9769.
108. Inoki K., et al. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
109. Jacinto E., et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 2004, 6:1122-1128.
110. Sarbassov D.D., et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
111. Huang J., et al. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell Biol. 2008, 28:4104-4115.
112. Huang J., Manning B.D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 2009, 37:217-222.
113. Sarbassov D.D., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
114. Lainhart J.E., et al. Head circumference and height in autism: a study by the Collaborative Program of Excellence in Autism. Am. J. Med. Genet. A 2006, 140:2257-2274.
115. Courchesne E., et al. Evidence of brain overgrowth in the first year of life in autism. J. Am. Med. Assoc. 2003, 290:337-344.
116. Courchesne E., et al. Mapping early brain development in autism. Neuron 2007, 56:399-413.
117. Chiu S., et al. Early acceleration of head circumference in children with fragile X syndrome and autism. J. Dev. Behav. Pediatr. 2007, 28:31-35.
118. Uhlmann E.J., et al. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia 2004, 47:180-188.
119. Uhlmann E.J., et al. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells. Oncogene 2002, 21:4050-4059.
120. Oshiro N., et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 2004, 9:359-366.
121. Veverka V., et al. Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene 2008, 27:585-595.
122. Guertin D.A., Sabatini D.M. The pharmacology of mTOR inhibition. Sci. Signal. 2009, 2:pe24.
123. Franz D.N., et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 2006, 59:490-498.
124. Bissler J.J., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 2008, 358:140-151.
125. Davies D.M., et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N. Engl. J. Med. 2008, 358:200-203.
126. de Vries P.J. Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex. Neurotherapeutics 2010, 7:275-282.
127. Berry-Kravis E., et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J. Dev. Behav. Pediatr. 2008, 29:293-302.
128. Berry-Kravis E.M., et al. A pilot open-label single-dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. 2009, 46:266-271.
129. Krab L.C., et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. J. Am. Med. Assoc. 2008, 300:287-294.